A significant rally on Friday provided Evonik shareholders with more than just a positive end to the trading week. The company’s stock closed at €16.26, marking a gain exceeding five percent. This move allowed the equity to decisively breach several key technical resistance levels simultaneously, supported by tangible fundamental developments.
Fundamental Backing for the Rally
The recent price action is underpinned by more than just chart patterns. On March 24, Evonik launched its “Innovation Factory,” a new unit replacing the former Creavis research platform. The objective is clear: to develop programs to production maturity within an average of five years. Initial focus areas include biopolymers and rhamnolipids—biodegradable surfactants already used in cleaning and cosmetic products, which are now targeted for scaling into additional market segments.
Financially, the company’s foundation appears solid. For 2025, Evonik confirmed an adjusted EBITDA of €1.87 billion on sales of €14.1 billion. Group net income climbed to €265 million, up from €222 million the previous year. A cash conversion rate of 37% landed at the upper end of the target range, providing flexibility for both debt reduction and future investment.
Should investors sell immediately? Or is it worth buying Evonik?
Looking ahead to 2026, management anticipates an adjusted EBITDA between €1.7 billion and €2.0 billion. Furthermore, a revised dividend policy has been introduced: starting with the current fiscal year, the company intends to distribute 40% to 60% of its adjusted group net income. For the 2025 fiscal year, the board will propose a dividend of €1.00 per share at the Annual General Meeting on June 3.
A Pivotal Technical Move
From a chart perspective, the most critical development was the breakout above the 200-day moving average, which was recently situated near €14.87. This long-term trend indicator is widely watched by market participants; a sustained move above it typically signals an improving technical outlook. The stock has now gained approximately 29% from its January low of €12.63. For the week, the advance totaled nearly 17%, and year-to-date performance stands at around 22%, significantly outpacing the MDAX index during the same periods.
The crucial question now is whether the €16-€17 zone will establish a new support base or merely represent a temporary plateau. The answer likely hinges on the Innovation Factory’s ability to deliver on its promise of accelerating the commercialization of new technologies. The first measurable results from this strategic shift are not expected to become visible until the upcoming quarterly reports.
Ad
Evonik Stock: Buy or Sell?! New Evonik Analysis from March 29 delivers the answer:
The latest Evonik figures speak for themselves: Urgent action needed for Evonik investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 29.
Evonik: Buy or sell? Read more here...
